FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2258542938> ?p ?o ?g. }

• W2258542938 endingPage "355" @default.
• W2258542938 startingPage "346" @default.
• W2258542938 abstract "Downregulation of the unfolded protein response mediates proteasome inhibitor resistance in multiple myeloma. The Human Immunodeficieny Virus protease inhibitor nelfinavir activates the unfolded protein response in vitro. We determined dose-limiting toxicity and recommended dose for phase II of nelfinavir in combination with the proteasome inhibitor bortezomib. Twelve patients with advanced hematologic malignancies were treated with nelfinavir (2500–5000 mg/day p.o., days 1–14, 3+3 dose escalation) and bortezomib (1.3 mg/m2, days 1, 4, 8, 11; 21-day cycles). A run in phase with nelfinavir monotherapy allowed pharmakokinetic/pharmakodynamic assessment of nelfinavir in the presence or absence of concomittant bortezomib. End points included dose-limiting toxicity, activation of the unfolded protein response, proteasome activity, toxicity and response to trial treatment. Nelfinavir 2×2500 mg was the recommended phase II dose identified. Nelfinavir alone significantly up-regulated expression of proteins related to the unfolded protein response in peripheral blood mononuclear cells and inhibited proteasome activity. Of 10 evaluable patients in the dose escalation cohort, 3 achieved a partial response, 4 stable disease for 2 cycles or more, while 3 had progressive disease as best response. In an exploratory extension cohort with 6 relapsed, bortezomib-refractory, lenalidomide-resistant myeloma patients treated at the recommended phase II dose, 3 reached a partial response, 2 a minor response, and one progressive disease. The combination of nelfinavir with bortezomib is safe and shows promising activity in advanced, bortezomib-refractory multiple myeloma. Induction of the unfolded protein response by nelfinavir may overcome the biological features of proteasome inhibitor resistance." @default.
• W2258542938 created "2016-06-24" @default.
• W2258542938 creator A5016787940 @default.
• W2258542938 creator A5018939058 @default.
• W2258542938 creator A5022167252 @default.
• W2258542938 creator A5025499001 @default.
• W2258542938 creator A5025804381 @default.
• W2258542938 creator A5029972979 @default.
• W2258542938 creator A5032114353 @default.
• W2258542938 creator A5033767394 @default.
• W2258542938 creator A5039080760 @default.
• W2258542938 creator A5041259777 @default.
• W2258542938 creator A5041795237 @default.
• W2258542938 creator A5043426460 @default.
• W2258542938 creator A5045139107 @default.
• W2258542938 creator A5046496560 @default.
• W2258542938 creator A5050776115 @default.
• W2258542938 creator A5051714210 @default.
• W2258542938 creator A5056439801 @default.
• W2258542938 date "2015-12-11" @default.
• W2258542938 modified "2023-10-01" @default.
• W2258542938 title "Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)" @default.
• W2258542938 cites W1672219033 @default.
• W2258542938 cites W1944289918 @default.
• W2258542938 cites W1963524125 @default.
• W2258542938 cites W1970833175 @default.
• W2258542938 cites W1977603207 @default.
• W2258542938 cites W1978377409 @default.
• W2258542938 cites W1986312696 @default.
• W2258542938 cites W1996308435 @default.
• W2258542938 cites W1999650826 @default.
• W2258542938 cites W2003734726 @default.
• W2258542938 cites W2009426416 @default.
• W2258542938 cites W2014003702 @default.
• W2258542938 cites W2026642838 @default.
• W2258542938 cites W2032584297 @default.
• W2258542938 cites W2034535492 @default.
• W2258542938 cites W2037132614 @default.
• W2258542938 cites W2039180923 @default.
• W2258542938 cites W2043943641 @default.
• W2258542938 cites W2044436186 @default.
• W2258542938 cites W2052645281 @default.
• W2258542938 cites W2060045688 @default.
• W2258542938 cites W2066699439 @default.
• W2258542938 cites W2071345969 @default.
• W2258542938 cites W2079167171 @default.
• W2258542938 cites W2080071021 @default.
• W2258542938 cites W2088303467 @default.
• W2258542938 cites W2089311432 @default.
• W2258542938 cites W2092159694 @default.
• W2258542938 cites W2104039873 @default.
• W2258542938 cites W2110506701 @default.
• W2258542938 cites W2113067867 @default.
• W2258542938 cites W2121595165 @default.
• W2258542938 cites W2126267349 @default.
• W2258542938 cites W2133201432 @default.
• W2258542938 cites W2135364779 @default.
• W2258542938 cites W2136541422 @default.
• W2258542938 cites W2141741074 @default.
• W2258542938 cites W2144769066 @default.
• W2258542938 cites W2150555063 @default.
• W2258542938 cites W2151092952 @default.
• W2258542938 cites W2166630192 @default.
• W2258542938 cites W2254386269 @default.
• W2258542938 doi "https://doi.org/10.3324/haematol.2015.135780" @default.
• W2258542938 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4815726" @default.
• W2258542938 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26659919" @default.
• W2258542938 hasPublicationYear "2015" @default.
• W2258542938 type Work @default.
• W2258542938 sameAs 2258542938 @default.
• W2258542938 citedByCount "42" @default.
• W2258542938 countsByYear W22585429382017 @default.
• W2258542938 countsByYear W22585429382018 @default.
• W2258542938 countsByYear W22585429382019 @default.
• W2258542938 countsByYear W22585429382020 @default.
• W2258542938 countsByYear W22585429382021 @default.
• W2258542938 countsByYear W22585429382022 @default.
• W2258542938 countsByYear W22585429382023 @default.
• W2258542938 crossrefType "journal-article" @default.
• W2258542938 hasAuthorship W2258542938A5016787940 @default.
• W2258542938 hasAuthorship W2258542938A5018939058 @default.
• W2258542938 hasAuthorship W2258542938A5022167252 @default.
• W2258542938 hasAuthorship W2258542938A5025499001 @default.
• W2258542938 hasAuthorship W2258542938A5025804381 @default.
• W2258542938 hasAuthorship W2258542938A5029972979 @default.
• W2258542938 hasAuthorship W2258542938A5032114353 @default.
• W2258542938 hasAuthorship W2258542938A5033767394 @default.
• W2258542938 hasAuthorship W2258542938A5039080760 @default.
• W2258542938 hasAuthorship W2258542938A5041259777 @default.
• W2258542938 hasAuthorship W2258542938A5041795237 @default.
• W2258542938 hasAuthorship W2258542938A5043426460 @default.
• W2258542938 hasAuthorship W2258542938A5045139107 @default.
• W2258542938 hasAuthorship W2258542938A5046496560 @default.
• W2258542938 hasAuthorship W2258542938A5050776115 @default.
• W2258542938 hasAuthorship W2258542938A5051714210 @default.
• W2258542938 hasAuthorship W2258542938A5056439801 @default.
• W2258542938 hasBestOaLocation W22585429381 @default.
• W2258542938 hasConcept C126322002 @default.

• next